Interview: Data And Connected Insight In Arthroplasty Will Take Corin Beyond COVID

Private UK orthopedic company has its own take on innovation that creates health care value

Corin has transformed from a niche UK hip resurfacing company into an innovative global player in orthopedics with a portfolio that includes robotics. UK managing director Paul Gibbons explained the group’s approach to business during COVID-19, and its culture of innovation.

Hip replacement

The two-decade journey of Corin Orthopaedics Holdings Limited through the orthopedics market, changing its portfolio and being taken into private equity, latterly under the ownership of Permira, has been nothing if not compelling. Not that the directors of the UK-based hip and knee arthroplasty specialist would have described it that way when the US metal-on-metal hip resurfacing issue in 2011 ended Stryker’s interest in hips, and thereby also its 10-year distribution agreement with Corin.

Corin had to look inwards, coming off the UK stock market, refinancing and assembling a new portfolio of technologies. It went under the radar for a while. It was later...

Arguably, the company has undergone its most progressive development in the past two years. The takeover by Permira freed up the company to invest in M&A and enabled more strategic...

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.